Edgar Filing: WATSON PHARMACEUTICALS INC - Form 4

WATSON P Form 4 May 07, 200'	HARMACEU 7	TICALS IN	٩C								
FORM								OMB APPROVAL			
-		SECURITIES AND EXCHANGE COMM Washington, D.C. 20549					OMB Number:	3235-0287			
Check thi if no long	or								Expires:	January 31, 2005	
subject to Section 1 Form 4 or	6. SIAI	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES								average Irs per	
Form 5 obligation may contri <i>See</i> Instru 1(b).	Filed Filed	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940							response	. 0.5	
(Print or Type R	Responses)										
1. Name and Address of Reporting Person <u>*</u> WEISS FRED G			2. Issuer Name and Ticker or Trading Symbol				-	5. Relationship of Reporting Person(s) to Issuer			
				WATSON PHARMACEUTICALS INC [WPI]					(Check all applicable)		
(Last) (First) (Middle) C/O FGW ASSOCIATES, 16450 MADDALENA PLACE			3. Date of Earliest Transaction(Month/Day/Year)05/04/2007					X_Director10% Owner Officer (give titleOther (specify below) below)			
	(Street)		4. If Amer	4. If Amendment, Date Original				6. Individual or Joint/Group Filing(Check			
DELRAY B	Filed(Mont	th/Day/Year)				Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting					
	(State)							Person			
(City)		(Zip)		e I - Non-D			ties Ac	quired, Disposed o		-	
1.Title of Security (Instr. 3)		2. Transaction Date 2A. Deemed (Month/Day/Year) Execution Date, if any (Month/Day/Year)			4. Securi onAcquired Disposed (Instr. 3,	l (A) c l of (E 4 and))	Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common				Code V	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)			
Stock, par value \$0.0033	05/04/2007			А	3,334 (1)	А	\$0	4,334 <u>(2)</u>	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: WATSON PHARMACEUTICALS INC - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Expiration D (Month/Day/ e	6. Date Exercisable and Expiration Date (Month/Day/Year)		le and unt of rlying rities . 3 and 4)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	

Reporting Owners

Reporting Owner Name / Address

Relationships



Х

WEISS FRED G C/O FGW ASSOCIATES **16450 MADDALENA PLACE** DELRAY BEACH, FL 33446

Signatures

/s/FRED G. 05/07/2007 WEISS

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The restricted stock was issued pursuant to the Second Amendment and Restatement of the 2001 Incentive Award Plan of Watson (1)Pharmaceuticals, Inc. and will vest on May 4, 2008.
- Includes shares of restricted stock issued pursuant to the Second Amendment and Restatement of the 2001 Incentive Award Plan of (2) Watson Pharmaceuticals, Inc.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.